AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04979715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: no intervention; preoperative patient informaiton and information leaflet
Study NCT02208635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified Maize
Description: Participants in this arm were fed zinc-oxide fortified maize (total level of \~60 µg Zn/g).
Study NCT02208635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Maize
Description: Participants in this arm were fed maize that was not fortified or biofortified (\~15 µg Zn/g maize).
Study NCT04465552 — intervention group
Intervention type: OTHER
Intervention: Patients received standard of care treatment during hospitalization
Description: All patients admitted with covid-19 will be enrolled and followed for the duration of their hospitalization as well as during outpatient follow for up to 6 months, in those recovered, to assess clinical outcomes.
Study NCT03917017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiomics and Watson artificial intelligence
Description: The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease.
Study NCT01505972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six and three time schedule
Description: Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
Study NCT01505972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four and two time schedule
Description: Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
Study NCT04570969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
Study NCT01886755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORS rehydration solution
Study NCT01945073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Booklet (BK)
Description: The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
Study NCT01945073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formal Counselling (CB)
Description: The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
Study NCT02912845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KamRAB - HRIG
Description: wound infiltration or IM injection
Study NCT01305174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROTEGE GPS stent vs. VISI-PRO stent
Description: Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
Study NCT03681236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment maneuver
Description: Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
Study NCT01877746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of prednisone and azathioprine
Description: * Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
Study NCT01877746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of prednisone and azathioprine
Description: * Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
Study NCT01877746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention, only standard medical therapy
Study NCT05040438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vax-NK/HCC
Description: autologous NK cells expanded ex vivo.
Study NCT00185276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
Study NCT00185276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
Study NCT04801199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL-2009-0031 140 mg
Description: Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
Study NCT01886755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03625492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Potentially Irritating Beverages
Description: This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
Study NCT03625492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adopting the USDA Healthy Eating Habits
Description: This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
Study NCT03077243 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: 60- 70 Gy at 2 Gy/fx
Study NCT03077243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or alternative)
Description: The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 -7 total doses.
Study NCT03268902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age
Study NCT03268902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age
Study NCT03268902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age
Study NCT02364479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg Yisaipu
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
Study NCT02364479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg etanercept
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
Study NCT02364479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The injection method and frequency of placebo is the same as the other arms.
Study NCT00730145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332334
Description: A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
Study NCT00841646 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Monovalent inactivated influenza vaccine
Description: 2 doses of monovalent inactivated influenza vaccine with adjuvant
Study NCT03608098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short Pulse Duration
Description: The holmium laser device will be used on a short laser pulse duration setting (300 μs or 350 μs)
Study NCT03608098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Pulse Duration
Description: The holmuim laser device will be used on a long laser pulse duration setting (700 μs or 1500 μs)
Study NCT01650844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-Based Telemedicine Enhanced Asthma Management
Study NCT01650844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Study NCT03478020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125
Description: Investigational Drug
Study NCT03478020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive
Description: COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
Study NCT04096963 — intervention group
Intervention type: DEVICE
Intervention: The WATCHMAN FLX Delivery System
Description: WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
Study NCT03868020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03868020 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study NCT03868020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT01958333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise 1
Description: Low-intensity, low-volume cardiorespiratory exercise and strength training
Study NCT01958333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise 2
Description: Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
Study NCT01958333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise 3
Description: High-intensity, High-volume cardiorespiratory exercise and strength training
Study NCT04027062 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Continuing Education Intervention
Description: The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians.
Study NCT02959320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Hemiarthroplasty
Description: This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
Study NCT01925534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow humidified nasal oxygen delivery system
Description: During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
Study NCT01925534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy
Description: During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
Study NCT03982407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET/MRI
Description: The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
Study NCT00957970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stemless femoral component
Description: Total hip femoral component anatomically designed for a proximal fit without a stem
Study NCT00957970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPS, Depuy cementless femoral stem
Description: Anatomical proximal fitted cementless stemmed femoral component
Study NCT03077243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment for surgical evaluation
Description: Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
Study NCT02793089 — intervention group
Intervention type: OTHER
Intervention: Analysis of Ectopic Pregnancy incidence
Description: Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
Study NCT03326661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration
Description: Needle aspiration of pus from the peritonsilar abscess
Study NCT03326661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy a chaud
Description: Removal of tonsil(s) due to peritonsillar abscess
Study NCT04801199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
Study NCT04310514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose/glucose/xylitol/saccharose
Description: 1. Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~2. Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~3. Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~4. Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.
Study NCT01943994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted treatment
Description: Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
Study NCT01943994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Study NCT04408872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Esophago-gastro-duodenoscopy (EGD)
Description: EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
Study NCT04408872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Description: EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
Study NCT01075152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
Study NCT01075152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
Study NCT01075152 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nucleoside
Description: Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
Study NCT01075152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nucleoside
Description: Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
Study NCT03326661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)
Description: patients treated with aspiration will receive antibiotic treatment
Study NCT01250743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ascorbic acid (vitamin C)
Description: intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
Study NCT03269136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06863135 monotherapy IV or SC
Description: PF-06863135 will be administered intravenously or subcutaneously.
Study NCT03269136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06863135 + dexamethasone
Description: PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
Study NCT03269136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06863135 + lenalidomide
Description: PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
Study NCT03269136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06863135 + pomalidomide
Description: PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
Study NCT03664635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
Study NCT02790684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Study NCT00145197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving the Delivery of Effective Care to Minorities
Description: The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
Study NCT02650440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Novel Protocol
Description: All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
Study NCT02650440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Protocol
Description: All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject